[3,4,6-Tris(acetyloxy)-5-dodecanamidooxan-2-YL]methyl acetate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [3,4,6-Tris(acetyloxy)-5-dodecanamidooxan-2-YL]methyl acetate
• 英文别名: [3,4,6-triacetyloxy-5-(dodecanoylamino)oxan-2-yl]methyl acetate
• 化学式: C₂₆H₄₃NO₁₀
• mdl: MFCD01326658
• 分子量: 529.6
• InChiKey: RMZJQKWFKJLFSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  37
• 可旋转键数：
  20
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS
  申请人：National Tuberous Sclerosis Association, Inc.

  公开号：US20190077874A1

  公开（公告）日：2019-03-14

  The treatment or prophylaxis of Tuberous Sclerosis Complex (“TSC”) and conditions associated with TSC is disclosed. Treatments involve the administration of one or more TLR4 inhibitors to patients with TSC. Such administration may also treat or forestall conditions associated with TSC, including epilepsy and lymphangioleiomyomatosis.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF TSC<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TSC
  申请人：NAT TUBEROUS SCLEROSIS ASSOCIATION INC

  公开号：WO2019055597A1

  公开（公告）日：2019-03-21

  The treatment or prophylaxis of Tuberous Sclerosis Complex ("TSC") and conditions associated with TSC is disclosed. Treatments involve the administration of one or more TLR4 inhibitors to patients with TSC. Such administration may also treat or forestall conditions associated with TSC, including epilepsy and lymphangioleiomyomatosis.